Pulse Stimulation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(2) Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPS) technology, today announced that the first CellFX procedures in the European Union were successfully completed. The initial commercial use of the non-thermal, cellular-focused CellFX System to clear common benign lesions, now expands the Company's controlled launch program starting with the top aesthetic dermatologists and plastic surgeons across Europe. This strategic rollout in Europe will run in parallel with the Company's U.S. controlled launch aimed at building a stro...

Press release content from Business Wire. The AP news staff was not involved in its creation. Pulse Biosciences Announces First CellFX Procedures Performed in Europe as Part of Global Controlled Launch February 19, 2021 GMT HAYWARD, Calif.--(BUSINESS WIRE)--Feb 19, 2021-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced that the first CellFX ® procedures in the European Union were successfully completed. The initial commercial use of the non-thermal, cellular-focused CellFX System to clear ...

Published: Feb 16, 2021 Pulse Biosciences Announces Start of Controlled Launch of the CellFX System ® - First Aesthetic Dermatology Patients Treated in the U.S.   HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced that the first clinic patients have been treated with the CellFX ® System. This first commercial use of the CellFX System marks the initiation of the Company’s controlled launch program with product shipments to respected leaders in dermato...